[Stroke and Other Thromboembolic Complications of Atrial Fibrillation. Part III. Prevention With Other Antithrombotic Agents.].
In part IV of a series of papers on epidemiology and drug prevention of stroke and other thromboembolic complications of atrial fibrillation the authors present data on clinical pharmacology of low molecular weight heparins, ximelagatran, indobufen, triflusal, dipyridamole, ticlopidine, and clopidogrel. Efficacy of direct thrombin inhibitor ximelagatran was found in randomized trials to be similar to efficacy of warfarin however the use of ximelagatran required no laboratory control of coagulation parameters. Preventive efficacy of indobufen, triflusal, dipyridamole, ticlopidine, and clopidogrel was assessed in trials on patients with cardiovascular diseases substantial number of whom had atrial fibrillation. Data of retrospective analysis of these trials are scrutinized in this review.
Presidential Medical Center of Russia; ul. Marshala Timoshenko, 15, 121356 Moscow, Russia; Sany Konukogly Medical Center, Gaziantep (Turkey).
D V
DV
Preobrazhenskiĭ
B A
BA
Sidorenko
V G
VG
Kiktev
T A
TA
Batyraliev
I V
IV
Pershukov
D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D012189:Retrospective Studies; D020521:Stroke; D014859:Warfarin / Q000627:therapeutic use
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014859:Warfarin